|
시장보고서
상품코드
2075735
글리코펩타이드 항생제 시장 : 약제별, 적응증별, 유통 채널별, 지역별 규모, 점유율, 전망 및 기회 분석(2025-2032년)Glycopeptide Antibiotics Market, by Drug, by Disease Indication, by Distribution channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
글리코펩타이드 항생제 시장은 2026년에 33억 7,930만 달러 규모에 이를 것으로 추정되며, 2033년까지 45억 6,810만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 4.4%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 33억 7,930만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 4.40% | 시장 규모 예측(2033년) : | 45억 6,810만 달러 |
글리코펩타이드 항생제는 펩타이드글리칸의 합성을 억제함으로써 세균의 세포벽 형성을 방해하는 유형의 항생제입니다. 글리코펩타이드 항생제는 클로스트리디움 디피실 관련 설사증, 심내막염, 장염, 입원 중 발병한 폐렴이나 인공호흡기 사용 중 발병한 폐렴, 그리고 중증 피부 및 피부 구조 감염증의 치료에 사용됩니다. 감염을 일으키는 세균에는 주로 두 가지 유형이 있습니다. 하나는 세포벽을 둘러싼 외막이 없는 그람 양성균이고, 다른 하나는 세포벽을 둘러싼 추가적인 외막을 가진 그람 음성균입니다. 그람 음성균은 외막을 통해 글리코펩타이드가 세포벽 내부로 침투하는 것을 막기 때문에 글리코펩타이드에 내성을 보이지만, 그람 양성균에 의한 감염증에는 글리코펩타이드가 효과적입니다.
또한, 중증 감염증의 경우 일부 글리코펩타이드 항생제가 정맥 주사로 투여되며, 경증 감염증의 경우 경구 투여가 이루어집니다. 황색포도상구균, 엔테로코커스 속, 클로스트리디움 디피실리 등 다제내성 그람양성균에 의해 유발되는 생명을 위협하는 감염증은 일반적으로 글리코펩타이드 항생제(GPA)를 사용하여 치료됩니다. 이 항생제 계열 중 하나는 식물이나 토양 세균에서 최초로 분리된, 글리코실화된 환상 또는 다환 구조의 비리보솜성 펩타이드를 포함하는 구조를 가지고 있습니다. 이러한 항생제는 펩티도글리칸의 생성을 억제함으로써, 감수성이 있는 미생물(주로 그람 양성 구균)의 세포벽 형성을 방해합니다. 반코마이신, 테이코플라닌, 라모플라닌은 1세대 글리코펩타이드 항생제의 예입니다. 오리타반신, 달바반신, 테라반신은 2세대 반합성 글리코펩타이드 항생제의 예입니다.
시장 역학
예측 기간 동안, 글리코펩타이드 항생제의 제품 출시 및 승인 건수 증가가 시장 성장을 견인할 것으로 예측됩니다. 예를 들어, 2019년 6월, 바이오의약품 기업인 ANI Pharmaceuticals, Inc.는 각종 감염증 치료를 목적으로 한 '반코마이신 염산염 경구용 액제 USP(250 mg/5 ml)'에 대해 미국 식품의약국(FDA)으로부터 사전 승인 보충 신청에 대한 승인을 받았습니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 파라미터(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 글리코펩타이드 항생제 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 글리코펩타이드 항생제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 글리코펩타이드 항생제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 글리코펩타이드 항생제 시장 : 약물별(2021-2033년)
제5장 세계의 글리코펩타이드 항생제 시장 : 질환 적응증별(2021-2033년)
제6장 세계의 글리코펩타이드 항생제 시장 : 유통 채널별(2021-2033년)
제7장 세계의 글리코펩타이드 항생제 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
AJY 26.07.09Glycopeptide Antibiotics Market is estimated to be valued at USD 3,379.3 Mn in 2026 and is expected to reach USD 4,568.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,379.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.40% | 2033 Value Projection: | USD 4,568.1 Mn |
Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.
Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.
Market Dynamics
Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global glycopeptide antibiotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market
Detailed Segmentation:
- Global Glycopeptide Antibiotics Market, By Drug (Revenue, USD Mn, 2021 - 2033)
- Vancocin
- Orbactiv
- Dalvance
- Kimyrsa
- Others
- Global Glycopeptide Antibiotics Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
- Clostridium difficile-associated Diarrhea
- Endocarditis
- Skin Structure Infections
- Others
- Global Glycopeptide Antibiotics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Glycopeptide Antibiotics Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest Of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- ANI Pharmaceuticals, Inc.*
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fresenius SE & Co. KGaA
- Pfizer Inc
- Mylan N.V.
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Cumberland Pharmaceuticals Inc
- Theravance Biopharma
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Development Strategies
- Mergers And Acquisition Scenario
- Market Trends
- Brand Analysis
- Regulatory Scenario
- PEST Analysis
- Pricing Analysis
4. Global Glycopeptide Antibiotics Market, By Drug, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Vancocin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Orbactiv
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Dalvance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Kimyrsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
5. Global Glycopeptide Antibiotics Market, By Disease Indication, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Clostridium difficile-associated Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Endocarditis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Skin Structure Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Glycopeptide Antibiotics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Global Glycopeptide Antibiotics Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- North America
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2021 - 2033, (US$ Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Competitive Snapshot
- ANI Pharmaceuticals, Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fresenius SE & Co. KGaA
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hikma Pharmaceuticals plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aurobindo Pharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Melinta Therapeutics, Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cumberland Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Theravance Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Janssen Global Services, LLC
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
